Sign In
Buy SAN
$12.47
+0.310 (+2.55%)
At Close: Jun 04, 2026
Press Release: Sanofi and IGM Biosciences Announce Collaboration Agreement for Oncology, Immunology and Inflammation Targets
05:00am, Tuesday, 29'th Mar 2022 GlobeNewswire Inc.
Sanofi and IGM Biosciences Announce Collaboration Agreement for Oncology, Immunology and Inflammation Targets
Communiqué de presse: Sanofi poursuit sa trajectoire de leadership en immunologie avec Dupixent® (dupilumab) comme levier de croissance
01:00am, Tuesday, 29'th Mar 2022 GlobeNewswire Inc.
Sanofi poursuit sa trajectoire de leadership en immunologie avec Dupixent® (dupilumab) comme levier de croissance
Press Release: Sanofi continues on path to industry leadership in Immunology with Dupixent® (dupilumab) as key driver
01:00am, Tuesday, 29'th Mar 2022 GlobeNewswire Inc.
Sanofi continues on path to industry leadership in Immunology with Dupixent® (dupilumab) as key driver
Press Release: Xenpozyme® (olipudase alfa) approved in Japan, first and only approved therapy indicated to treat acid sphingomyelinase deficiency
07:00am, Monday, 28'th Mar 2022 GlobeNewswire Inc.
Communiqué de presse : Approbation de Xenpozyme® (olipudase alpha) au Japon – premier et seul médicament approuvé pour le traitement du déficit en sphingomyélinase acide
07:00am, Monday, 28'th Mar 2022 GlobeNewswire Inc.
Sanofi: Informations relatives au nombre de droits de vote et d'actions – FEVRIER 2022
04:45pm, Saturday, 26'th Mar 2022 GlobeNewswire Inc.
Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L. 233-8 II du Code de commerce et l’article 223-16 du Règlement général de l’Autorité des Marc
Sanofi: Information concerning the total number of voting rights and shares – February 2022
04:45pm, Saturday, 26'th Mar 2022 GlobeNewswire Inc.
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement
Press release: Late-breaking Phase 3 data at AAD 2022 show Dupixent® (dupilumab) significantly improved signs and symptoms of prurigo nodularis
02:00pm, Saturday, 26'th Mar 2022 GlobeNewswire Inc.
Late-breaking Phase 3 data at AAD 2022 show Dupixent® (dupilumab) significantly improved signs and symptoms of prurigo nodularis
Communiqué de presse: Des données de phase III de dernière minute présentées au Congrès 2022 de l’AAD montrent que Dupixent® (dupilumab) améliore significativement les signes et symptômes du prurigo nodulaire
02:00pm, Saturday, 26'th Mar 2022 GlobeNewswire Inc.
Des données de phase III de dernière minute présentées au Congrès 2022 de l’AAD montrent que Dupixent® (dupilumab) améliore significativement les signes et symptômes du prurigo nodulaire
Why StoneCo Plummeted Today
06:46pm, Friday, 25'th Mar 2022 The Motley Fool
A board shake-up had investors selling on a bad day for growth stocks.
Benzinga's Top Ratings Upgrades, Downgrades For March 21, 2022
02:09pm, Monday, 21'st Mar 2022 Benzinga
Upgrades
According to B. Riley Securities, the prior rating for BRT Apartments Corp (NYSE:BRT) was changed from Neutral to Buy. BRT Apartments earned $0.41 in the fourth quarter, compared to $0.33 in
Press Release: Sanofi moves forward with EUROAPI listing on Euronext Paris
11:48am, Friday, 18'th Mar 2022 GlobeNewswire Inc.
Communiqué de presse : Sanofi lance le projet de cotation d'EUROAPI sur Euronext Paris
11:48am, Friday, 18'th Mar 2022 GlobeNewswire Inc.
HSBC to Shut 69 UK Branches Amid Shift to Digital Banking
02:06pm, Wednesday, 16'th Mar 2022 Zacks Investment Research
HSBC plans to shut 69 of its 510 bank branches in the U.K. as customers favor online banking over physical bank locations.
Communiqué de presse : Sanofi et Seagen annoncent leur collaboration pour le développement et la commercialisation de plusieurs nouveaux conjugués anticorps-médicament
10:18am, Wednesday, 16'th Mar 2022 GlobeNewswire Inc.
Sanofi et Seagen annoncent leur collaboration pour le développement et la commercialisation de plusieurs nouveaux conjugués anticorps-médicament
